Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Interferon gamma-1b
Drug ID BADD_D01171
Description Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Indications and Usage Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
Marketing Status Prescription
ATC Code L03AB03
DrugBank ID DB00033
KEGG ID D00747
MeSH ID C554125
PubChem ID Not Available
TTD Drug ID D0U9EN
NDC Product Code 17089-378; 75987-111
Synonyms interferon gamma-1b | interferon gamma-2a | Actimmune
Chemical Information
Molecular Formula Not Available
CAS Registry Number 98059-61-1
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AgitationGlutamate receptor ionotropic, NMDA 3AQ8TCU5Not AvailableNot Available
ApoptosisApoptosis regulator BAXQ07812T89251Not Available
ApoptosisNitric oxide synthase, brainP29475T16117Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase increased13.03.01.003--
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Atrioventricular block02.03.01.002--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac failure02.05.01.001--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chills08.01.09.001; 15.05.03.016--
Clubbing22.02.08.013; 15.03.02.006; 02.01.02.012--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Death08.04.01.001--
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.001--Not Available
Diarrhoea07.02.01.001--
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dyspepsia07.01.02.001--
Fatigue08.01.01.002--
Gait disturbance17.02.05.016; 08.01.02.002--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatomegaly09.01.05.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypertriglyceridaemia14.08.02.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Injection site erythema08.02.03.001; 23.03.06.015; 12.07.03.001--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages